248 related articles for article (PubMed ID: 19274429)
1. Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.
Zaccarelli M; Lorenzini P; Tozzi V; Forbici F; Ceccherini-Silberstein F; Gori C; D'Arrigo R; Trotta MP; Narciso P; Perno CF; Antinori A;
Infection; 2009 Jun; 37(3):203-9. PubMed ID: 19274429
[TBL] [Abstract][Full Text] [Related]
2. Virological Outcome After Choice of Antiretroviral Regimen Guided by Proviral HIV-1 DNA Genotyping in a Real-Life Cohort of HIV-Infected Patients.
Meybeck A; Alidjinou EK; Huleux T; Boucher A; Tetart M; Choisy P; Bocket L; Ajana F; Robineau O
AIDS Patient Care STDS; 2020 Feb; 34(2):51-58. PubMed ID: 32049556
[TBL] [Abstract][Full Text] [Related]
3. The V118I mutation as a marker of advanced HIV infection and disease progression.
Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
[TBL] [Abstract][Full Text] [Related]
4. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.
Easterbrook PJ; Ives N; Waters A; Mullen J; O'Shea S; Peters B; Gazzard BG
AIDS; 2002 Jul; 16(11):1521-7. PubMed ID: 12131190
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
[TBL] [Abstract][Full Text] [Related]
6. How relevant is the HIV low level viremia and how is its management changing in the era of modern ART? A large cohort analysis.
Taramasso L; Magnasco L; Bruzzone B; Caligiuri P; Bozzi G; Mora S; Balletto E; Tatarelli P; Giacomini M; Di Biagio A
J Clin Virol; 2020 Feb; 123():104255. PubMed ID: 31927152
[TBL] [Abstract][Full Text] [Related]
7. Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients.
; Vandenhende MA; Ingle S; May M; Chene G; Zangerle R; Van Sighem A; Gill MJ; Schwarze-Zander C; Hernandez-Novoa B; Obel N; Kirk O; Abgrall S; Guest J; Samji H; D'Arminio Monforte A; Llibre JM; Smith C; Cavassini M; Burkholder GA; Shepherd B; Crane HM; Sterne J; Morlat P
AIDS; 2015 Jan; 29(3):373-83. PubMed ID: 25686685
[TBL] [Abstract][Full Text] [Related]
8. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
[TBL] [Abstract][Full Text] [Related]
10. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
11. Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.
Badri SM; Adeyemi OM; Max BE; Hota BN; Barker DE
AIDS Patient Care STDS; 2007 Aug; 21(8):544-50. PubMed ID: 17711379
[TBL] [Abstract][Full Text] [Related]
12. Effect of persistent moderate viremia on disease progression during HIV therapy.
Raffanti SP; Fusco JS; Sherrill BH; Hansen NI; Justice AC; D'Aquila R; Mangialardi WJ; Fusco GP;
J Acquir Immune Defic Syndr; 2004 Sep; 37(1):1147-54. PubMed ID: 15319674
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
[TBL] [Abstract][Full Text] [Related]
14. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
[TBL] [Abstract][Full Text] [Related]
15. Genotype-Informed Versus Empiric Management Of VirEmia (GIVE MOVE): study protocol of an open-label randomised clinical trial in children and adolescents living with HIV in Lesotho and Tanzania.
Brown JA; Ringera I; Luoga E; Cheleboi M; Kimera N; Muhairwe J; Kayembe BP; Molapo Hlasoa M; Kabundi L; Yav CWD; Mothobi B; Thahane L; Amstutz A; Bachmann N; Mollel GJ; Bresser M; Glass TR; Paris DH; Klimkait T; Weisser M; Labhardt ND
BMC Infect Dis; 2020 Oct; 20(1):773. PubMed ID: 33076866
[TBL] [Abstract][Full Text] [Related]
16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
17. Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?
Mzingwane ML; Tiemessen CT; Richter KL; Mayaphi SH; Hunt G; Bowyer SM
Virol J; 2016 Oct; 13(1):170. PubMed ID: 27733203
[TBL] [Abstract][Full Text] [Related]
18. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
[TBL] [Abstract][Full Text] [Related]
19. Impact of Low-level Viremia on Treatment Outcomes During ART - Is it Time to Revise the Definition of Virological Failure?
Poveda E; Crespo M
AIDS Rev; 2018; 20(1):71-72. PubMed ID: 29628513
[TBL] [Abstract][Full Text] [Related]
20. [Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].
Parra-Ruiz J; Alvarez M; Chueca N; Peña A; Pasquau J; López-Ruz MA; Maroto Mdel C; Hernández-Quero J; García F
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):75-80. PubMed ID: 19254638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
